Grok LawX Freeze (@XFreeze):Grok-4.20 just ranked #1 in Legal & Government on Chatbot ArenaIt’s officially outperforming Anthropic’s Opus 4.6 and Google’s Gemini 3.1 ProGrok is actively helping people navigate real lawsuits and do complex tax management (I've been personally using it for my own taxes) https://t.co/bOfouqEz7C ...

Core Viewpoint - A class action lawsuit has been filed against Pinterest, Inc. (PINS) for securities fraud, affecting investors who purchased shares between February 7, 2025, and February 12, 2026, with a deadline for filing a lead plaintiff motion set for May 29, 2026 [1][2]. Financial Performance - On November 4, 2025, Pinterest reported third quarter 2025 financial results, with a fourth quarter revenue guidance midpoint of $1.325 billion, which was below the consensus expectation of $1.34 billion, citing moderating ad spend from larger U.S. retailers due to tariff-related margin pressures [3]. - Following this announcement, Pinterest's stock price dropped by $7.16, or 21.8%, closing at $25.75 per share on November 5, 2025 [4]. - On January 27, 2026, Pinterest announced a global restructuring plan affecting less than 15% of its workforce and anticipated pre-tax restructuring charges of approximately $35 million to $45 million, primarily cash-related [5]. - This news led to a further decline in Pinterest's stock price by $2.49, or 9.6%, closing at $23.41 per share on January 27, 2026 [5]. - On February 12, 2026, Pinterest released its fourth quarter 2025 financial results, reporting revenue of $1.32 billion, below the consensus estimate of $1.33 billion, and provided Q1 2026 revenue guidance of $951 million to $971 million, also below expectations [6]. - The stock price fell again by $3.12, or 16.8%, closing at $15.42 per share on February 13, 2026 [7]. Allegations in the Lawsuit - The lawsuit alleges that Pinterest made materially false and misleading statements and failed to disclose adverse facts about its business and operations during the class period [7]. - Specific allegations include: (1) reduced revenues from advertising partners, (2) overstated ability to manage tariff impacts, (3) significant impact on advertising revenues leading to imminent restructuring, and (4) misleading positive statements about the company's prospects [7].

Core Viewpoint - Faruqi & Faruqi, LLP is reminding investors of Ramaco Resources, Inc. about the deadline for a securities class action lawsuit, which is set for March 31, 2026, encouraging affected investors to discuss their legal options [1][2]. Group 1: Legal Action and Allegations - The firm is investigating potential claims against Ramaco Resources, Inc. (NASDAQ: METC) and has filed a federal securities class action against the company [2]. - The complaint alleges that Ramaco and its executives violated federal securities laws by making false or misleading statements regarding the company's mining activities, specifically at the Brook Mine [4]. - Allegations include that no significant mining activity had commenced at the Brook Mine after its groundbreaking, and that the company overstated its development progress [4]. Group 2: Impact on Stock Price - Following a report by Wolfpack Research on October 23, 2025, which described the Brook Mine as a "hoax" and claimed no active work was being conducted, Ramaco's stock price fell by $3.81, or 9.6%, closing at $36.01 per share on unusually high trading volume [5]. Group 3: Class Action Participation - The lead plaintiff in the class action will be the investor with the largest financial interest who is also typical of class members, and any member of the class can move the court to serve as lead plaintiff [6]. - Investors are encouraged to contact Faruqi & Faruqi for more information, including whistleblowers and former employees [7].

Core Viewpoint - Halper Sadeh LLC is investigating whether Centessa Pharmaceuticals plc is obtaining a fair price for its shareholders in the proposed sale to Eli Lilly and Company for $38.00 in cash per share plus a contingent value right worth up to $9.00 based on certain milestones [3]. Group 1: Investigation Details - The investigation focuses on whether Centessa and its board violated federal securities laws and/or breached fiduciary duties by failing to secure the best possible price for shareholders, conduct a fair sales process, and disclose all material information necessary for shareholders to evaluate the transaction [5]. - The proposed transaction may include terms that could limit superior competing offers, potentially disadvantaging ordinary shareholders [1]. Group 2: Shareholder Rights - Shareholders are encouraged to contact Halper Sadeh LLC to discuss their rights and options at no cost, with the firm operating on a contingent fee basis [2][4]. - Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief and benefits on behalf of shareholders [6].

Core Viewpoint - The Schall Law Firm is investigating ePlus inc. for potential violations of securities laws, focusing on whether the company made false or misleading statements and failed to disclose important information to investors [2]. Group 1: Investigation Details - The investigation is centered on ePlus's Q3 financial results announced on February 5, 2025, which fell short of consensus estimates, attributed to "digestion" in the networking space and select enterprise customers [2]. - Following the announcement of the disappointing financial results, ePlus's shares experienced a significant decline of 13.1% the next day [2]. Group 2: Investor Participation - Shareholders who have suffered losses are encouraged to participate in the investigation and can contact the Schall Law Firm for more information [3].

Core Viewpoint - Vital Farms, Inc. is facing a class action lawsuit for securities fraud due to misleading statements regarding the impact of delays related to its new enterprise resource planning (ERP) system [4]. Group 1: Lawsuit Details - The Schall Law Firm is leading a class action lawsuit against Vital Farms for violations of the Securities Exchange Act of 1934 [1]. - Investors who purchased securities between May 8, 2025, and February 26, 2026, are encouraged to participate in the lawsuit before the deadline of May 26, 2026 [2]. - The lawsuit claims that Vital Farms made false statements about the risks associated with its ERP system, which ultimately led to missed earnings per share [4]. Group 2: Investor Information - The Schall Law Firm specializes in securities class action lawsuits and is representing investors globally [5]. - Investors who suffered losses due to the misleading statements are invited to contact the firm for a free discussion of their rights [3].

Core Viewpoint - China Liberal Education Holdings Limited (CLEUF) is facing a securities fraud class action lawsuit due to significant stock price decline and misleading information provided to investors [2][3]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of investors who acquired CLEUF securities between January 22, 2025, and January 30, 2025, with a deadline to participate as a lead plaintiff by March 31, 2026 [1][4]. - The lawsuit alleges that CLEUF made materially false and misleading statements and failed to disclose adverse facts about its business and operations [3][4]. Group 2: Stock Price Impact - On January 29, 2025, CLEUF reported 240 million previously undisclosed exchanged shares, leading to a stock price drop from $7.75 to $0.148 per share, representing a 98.1% loss [2][3]. - Following the stock price decline, CLEUF was delisted by NASDAQ in June 2025 [3]. Group 3: Nature of Misleading Information - The lawsuit claims that CLEUF shares were involved in a pump-and-dump scam, and that certain financial advisors provided false and misleading information [3]. - The complaint highlights that positive statements made by CLEUF regarding its business lacked a reasonable basis and were materially misleading [3].

Core Viewpoint - Investors in ImmunityBio, Inc. (NASDAQ: IBRX) have the opportunity to lead a securities fraud lawsuit against the company due to alleged violations of the Securities Exchange Act of 1934 [1][4]. Group 1: Lawsuit Details - The Schall Law Firm is reminding investors of a class action lawsuit against ImmunityBio for making false and misleading statements regarding its Anktiva drug [1][4]. - The class period for the lawsuit is defined as January 19, 2026, to March 24, 2026, during which investors who purchased the company's securities may have suffered losses [2][4]. - Investors are encouraged to contact the Schall Law Firm before May 26, 2026, to discuss their rights and potential participation in the lawsuit [2][3]. Group 2: Company Allegations - The complaint alleges that ImmunityBio overstated the capabilities of its Anktiva drug, leading to materially misleading public statements throughout the class period [4]. - The lawsuit claims that when the truth about ImmunityBio's statements was revealed, investors experienced significant damages [4]. Group 3: Legal Representation - The Schall Law Firm specializes in securities class action lawsuits and represents investors globally [5]. - Investors can reach out to the firm for a free discussion regarding their rights and potential involvement in the lawsuit [3][5].

Core Viewpoint - The Schall Law Firm is investigating Vertical Aerospace Ltd. for potential violations of securities laws, particularly focusing on misleading statements and undisclosed information that may have affected investors [1][2]. Group 1: Company Financials and Concerns - Vertical Aerospace filed its annual report for 2025 with the SEC on March 24, 2026, indicating significant financial concerns, including limited cash, recurring operational losses, and a dependency on raising additional capital, which raises doubts about the company's ability to continue as a going concern [2]. - Following the release of this report, shares of Vertical Aerospace fell by nearly 18.2% on the same day, reflecting investor reaction to the disclosed financial uncertainties [2]. Group 2: Legal Actions and Investor Opportunities - The Schall Law Firm is inviting shareholders who have suffered losses to participate in the investigation and discuss their rights [3]. - The firm specializes in securities class action lawsuits and shareholder rights litigation, indicating a focus on protecting investor interests [3].

Core Viewpoint - Kirby McInerney LLP is investigating potential securities fraud claims against ADMA Biologics, Inc., focusing on possible violations of federal securities laws and unlawful business practices by the company and its senior management [1][2]. Group 1: Investigation Details - The investigation was prompted by a report from Culper Research on March 24, 2026, alleging that ADMA engaged in "Channel Stuffing" and had undisclosed related party distributors, with a reported growth of +20% in 2025 being misleading as the actual growth was only -3% [2]. - The report indicated that two high-level employees from one of ADMA's largest distributors confirmed that ADMA induced the distributor to stock excess ASCENIV by offering rebates and extended payment terms, allowing the company to book revenues that did not reflect actual sales [2]. Group 2: Market Reaction - Following the publication of the report, ADMA's share price fell by $2.26, or approximately 17%, dropping from $13.59 on March 23, 2026, to close at $11.33 on March 24, 2026 [2].